1. The use of adenosine in the treatment of a high-flow vein of Galen malformation in an adult
- Author
-
L. Fernando Gonzalez, Nohra Chalouhi, Aaron S. Dumont, Robert H. Rosenwasser, Jonathan D. Halevy, Pascal Jabbour, Stavropoula Tjoumakaris, Asterios Tsimpas, and Stephen J. Monteith
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adenosine ,Vasodilator Agents ,law.invention ,law ,Physiology (medical) ,medicine ,Humans ,Vein ,Interventional neuroradiology ,business.industry ,Angiography, Digital Subtraction ,General Medicine ,medicine.disease ,Surgery ,Vein of Galen aneurysmal malformations ,medicine.anatomical_structure ,Neurology ,Cyanoacrylate ,Heart failure ,Vein of Galen Malformations ,Neurology (clinical) ,Neurosurgery ,Headaches ,medicine.symptom ,business ,medicine.drug - Abstract
The treatment of high-flow vein of Galen aneurysmal malformations (VGAM) remains a therapeutic challenge for the neurosurgeon and the neurointerventionalist, as it is associated with high morbidity and mortality rates despite recent advances in open cranial surgery and interventional neuroradiology. A 37-year-old patient presented with a history of non-specific headaches. He had a history of heart failure since birth that was caused by an untreated VGAM. Intravenous boluses of adenosine were injected as an attempt to slow down the arteriovenous shunting of a VGAM prior to endovascular treatment. Adenosine can be a very useful adjunct in patients with extremely high arteriovenous shunting. n-butyl cyanoacrylate (n-BCA) should be the embolic material of choice due to its quick polymerization and adhesive properties.
- Published
- 2014
- Full Text
- View/download PDF